I now see that Palatin has commenced a P2 trial for ED (n=50, topline results 6/12). Palatin are trialling MT2 for ED and weight loss. both in combination with PDE5i and GLP1 drugs. Weight loss, frying pan handle boners, if only there was a way of getting a tan. The ultimate barbie drug.
- Forums
- ASX - By Stock
- CUV
- Ann: CLINUVEL Newsletter III - June 2024
Ann: CLINUVEL Newsletter III - June 2024, page-32
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.66 |
Change
-0.080(0.54%) |
Mkt cap ! $735.1M |
Open | High | Low | Value | Volume |
$14.74 | $14.77 | $14.50 | $361.9K | 24.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 70 | $14.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.67 | 69 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 97 | 14.670 |
6 | 86 | 14.660 |
5 | 254 | 14.650 |
4 | 208 | 14.640 |
3 | 181 | 14.630 |
Price($) | Vol. | No. |
---|---|---|
14.680 | 14 | 1 |
14.690 | 35 | 2 |
14.700 | 49 | 1 |
14.710 | 281 | 4 |
14.720 | 164 | 3 |
Last trade - 13.51pm 30/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online